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ABSTRACT 
Objective :The purpose of this study was to investigate the efficacy and safety 
of Fixed Dose Combination (FDC) of olanzapine 5 mg and fluoxetine 20 mg in 
Indian patients with severe or treatment resistant depression. 
Design :This was an open, non-comparative study of seven weeks duration 
an initial placebo run in period of one week. 
with 
Method : One hundred and fifty three patients were enrolled. One hundred and 
forty-four patients completed the study as per protocol and 151 patients were 
safety evaluable. One hundred and eleven patients (77%) received one tablet of 
FDC of olanzapine 5 mg / fluoxetine 20 mg once daily for 6 weeks, in patients 
(14%), the dose was stepped up at the end of 2 weeks to 2 tablets of FDC of 
olanzapine 5 mg/ fluoxetine 20 mg once daily for a further 4 weeks and 13 patients 
(9%) required dose to be stepped up at the end of 4 weeks to 3 tablets of 
FDC of olanzapine 5 mg and fluoxetine 20 mg once daily for last 2 weeks. 
Results : One hundred and thirty four patients (93%) responded to FDC 
of olanzapine and fluoxetine therapy (a responder was defined as a patient with 
50 % reduction over baseline in HDRS total score at the end of therapy). 
Statistically significant (p< 0.0001) reductions in HDRS total score, MADRS total 
score and CGI severity scores were seen with olanzapine/ fluoxetine combination. 
One hundred and four patients (72%) were remitters (HDRS total score of 
<7) after 6 weeks of therapy. 
Adverse experiences were reported by thirty one patients (20.5%). Majority 
of them were mild in intensity. No serious adverse event was recorded with 
study therapy. Three patients were withdrawn from the therapy due to adverse 
event. 
Conclusion : Treatment with FDC of olanzapine 5 mg / fluoxetine 20 mg was 
highly effective and well tolerated in Indian patients with severe or treatment 
resistant depression. 
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INTRODUCTION 
Current antidepressant treatments do not 
help every patient with depression. Up to 
30 percent of patients with major depressive 
disorder are resistant to conventional 
antidepressant treatment (Roose et al, 1986; 
Amsterdam & Harrig-Rohan, 1996; Fawat 
1994). Treatment resistant depression, 
commonly defined as the failure to respond 
to two or more treatment trials widi 
medication from different pharmacological 
classes (Nirenberg & Amsterdam, 1990), is 
a routinely encountered disorder often 
associated with severe functional impairment, 
morbidity and delayed recovery. 
Medical therapy for such resistant 
disorders, include combinations of 
antidepressants or various augmentation 
strategies such as combined antidepressant-
antipsychotic approach. Antipsychotic agents 
may exhibit antidepressant activity, either 
alone or in combination with an anti-
depressant ((Robertson & Trimble 1982), 
particularly in depression with psychotic 
features (Wolfersdorf et al, 1995; Rothchild 
et al, 1993; Wolforsolrf et al, 1994; Spiker, 
1985). However, widespread application of 
augmentation with typical antipsychotics has 
been largely precluded by the high risk of 
extra pyramidal symptoms and/or tardive 
dyskinesia (Jeste & Caligiuri, 1993; Casey, 
1993). In contrast novel antipsychotic agents 
such as olanzapine exhibit a substantially 
lower risk of extrapyramidal symptoms and 
tardive dyskinesia (Tollefson et al, 1997; 
Teran et al, 1997). 
The aim of this study was to assess the 
efficacy and tolerability of FDC of the 
atypical antipsychotic agent olanzapine in 
combination with the selective serotonin 
reuptake inhibitor antidepressant agent 
fluoxetine in Indian patients suffering from 
severe or resistant depression. 
MATERIAL AND METHODS 
Study design 
This was an open, non-comparative study 
with a placebo run in period of 1 week, 
followed by active treatment period of two 
weeks at the end of which the dose was 
to be stepped up if clinically indicated. 
However, patients not on antidepressants 
for 1 week before study entry were to enter 
the active treatment phase without having 
to go through placebo run-in period. 
Each patient was to receive active 
treatment for six weeks at the initial (one 
tablet of FDC of olanzapine 5 mg and 
fluoxetine 20 mg once daily) or stepped up 
(two or three tablets of FDC of olanzapine 
5 mg and fluoxetine 20 mg once daily) dose 
level. 
Inclusion criteria 
Patients of either sex, aged 18-60 years, 
fulfilling Diagnostic and Statistic Manual IV 
(DSM-IV) Diagnostic Criteria for Major 
(234) HAMDASetal 
Depression and having severe depression [a 
total score of 20 or more on Hamilton 
Depression Rating Scale (HDRS)j or resistant 
depression (defined as failure to respond to 
antidepressants of two different classes (one 
of which is not an SSRI) after at least 4 
weeks of therapy at acceptable therapeutic 
dose|. 
Exclusion criteria 
Patients with a primary psychiatric 
disorder other than depression; patients 
with history of psychosis, dysthymic disorder 
or bipolar disorder; patients posing a 
serious suicide risk or severely retarded 
patients; patients with a baseline HDRS 
total scote of <20; patients with a history 
of alcohol or drug dependence (except 
nicotine) in the last six months; pregnant 
or breast feeding women; patients with a 
history of hypersensitivity to olanzapine 
and/or fluoxetine. 
Efficacy and safety variables 
Hamilton Depression Rating Scale 
(HDRS) and Montgomery Asberg 
Depression Rating Scale (MADRS) were 
used to measure drug efficacy. The 17-
items in HDRS were depressed mood, guilt 
feelings and self depreciation, suicidal 
impulses, initial insomnia, middle insomnia, 
late insomnia, work and interests, retardation, 
agitation, psychic anxiety, somatic anxiety, 
gastrointestinal symptoms, general somatic 
symptoms, sexual interests, hypochondriasis, 
loss of insight and weight loss. Apparent 
sadness, reported sadness, inner tension, 
reduced sleep, reduced appetite, 
concentration difficulties, lassitude, inability 
to feel, suicidal thought and pessimistic 
thoughts were the 10-items in MADRS. 
Severity of illness and global improvement 
was measured on the Clinical Global,, 
Impression (CGI) scale. *[• 
Safety variables were assessed by recording 
adverse events as to their type, severity and 
causal relationship to therapy. 
Statistical Analysis 
The change from baseline in the total 
HDRS, HDRS Item No. 1 (depressed mood) 
score, total MADRS score and the CGI 
severity score were analyzed using Wilcoxon's 
Signed Rank Test. Alpha was set at 0.05. 
Proportion of responders defined as 50% 
reduction over baseline in total HDRS score 
and proportion of remitters (total HDRS 
score of <7) after 6 weeks of therapy with 
FDC of olanzapine and fluoxetine has also 
been reported. Patients who had at least 
one post therapy evaluation were considered 
in intent-to-treat analysis. All patients who 
did not complete entire duration of study 
but included in intent-to-treat analysis were 
considered as non-responders. 
RESULTS 
Demographic Data 
The demographic profile of patients 
entering the study is illustrated in Table 1. 
One hundred and fifty three patients (54% 
male and 46% female) enrolled in this study 
had a mean age of 35.8 years and mean 
body weight 56.6 kgs. 
At the end of study 144 patients were 
evaluated for efficacy by per protocol analysis 
and 151 patients for intent-to-treat and 
safety analysis. 
TABLE I 
demographics 
Summary of patient 
Total Number of Patients 153 
Sex M/F (% of patients) 54/46 
Age (years) 
Mean + SD 35.8 ± 9.3 
Range 18 - 56 
Weight (kg.) 
Mean + SD 56.6 ± 10.7 
Range 34 - 85 
Dosage and Duration of 
treatment 
One hundred and eleven patients (77%) 
received one tablet of FDC of olanzapine 
5 mg / fluoxetine 20 mg once daily for 
6 weeks, in 20 patients (14%), the dose 
was stepped up at the end of 2 weeks 
to 2 tablets of FDC of olanzapine 5 mg/ 
fluoxetine 20 mg once daily for a further 
4 weeks and 13 patients (9%) required 
dose to be stepped up at the end 
of 4 weeks to 3 tablets of FDC of 
olanzapine 5 mg and fluoxetine 20 mg once 
daily for last 2 weeks (Table 2). 
TABLE 2 : Dosage and Duration of 
Treatment (Per protocol population) 
[n=l44] 
Treatment  No. (%)of 
patients 
FDC of Olanzapine 5 mg and 
Fluoxetine 20 mg 
One tablet o.d. for 6 weeks 111 (77%) 
One tablet o.d. for 2 weeks 20 (14%) 
followed by 2 tablets o.d. 
for 4 weeks 
One tablet o.d. for 2 weeks, 13 (9%) 
2 tablets o.d. for next 2 weeks 
followed by 3 tablets o.d. 
for last 2 weeks 
TABLE 3 : Clinical Response to FDC 
of Olanzapine and Fluoxetine (>50% 
reduction over baseline in HDRS total 
score) 
Population  Percent of responders 
Intent-to-treat (n=151) 89% 
Per protocol (n=144) 93% 
TABLE 4 : Cumulative Response to FDC of Olanzapine and Fluoxetine as per 
last dose sequence (Per protocol population) (n=l44) 
Treatment  No.(%) of responders (>50% 
reduction in total HDRS score) 
FDC of Olanzapine 5 mg and Fluoxetine 20 mg 
Response to one tablet o.d. 109/144 (76%) 
Cumulative response to two tablets o.d. 127/144 (88%) 
Cumulative response to 3 tablets o.d 134/144 (93%) 
(23S) OLANZAPINE AND FLUOXETINE COMBINATION IN DEPRESSION 
TABLE 5 : Proportion of Reminers 
(HDRS total score < 7) 
Population Percent of remitters 
Per-protocol (n=144)  72% 
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Figure 2. 
Clinical Response *Rate to FDC of 
Olanzapine 5 mg and Fluoxetine 20 mg 
(Per-protocol population) 
* 50% reduction over baseline in total 
HDRS score 
Clinical Efficacy 
The proportion of responders (reduction 
of 50% over baseline in HDRS total score) 
in the intent-to-treat and per protocol 
population is depicted in Table 3. The 
response rate was 89% in the intent-to-treat 
population and 93% in the per protocol 
population. 
The clinical response at each dosage level 
of FDC of olanzapine 5 mg and fluoxetine 
TABLE 6 : Summary of depression scores (mean + SD) at baseline and final visit 
in patients treated with FDC of Olanzapine and Fluoxetine (All doses - Per 
protocol population)! n=l44 ] 
Parameter  Mean +SD Scores 
HDRS (total) 
Baseline 
Mean decrease 
Percentage decrease 
p-value* 
HDRS Item No. 1 (Depressed mood) 
Baseline 
Mean decrease 
Percentage decrease 
p-value* 
MADRS (total) 
Baseline 
Mean decrease 
Percentage decrease 
p-value* 
CGI Severity 
Baseline 
Mean decrease 
Percentage decrease 
p-value* 
CGI Improvement** 
Final visit 
29.27 ± 5.46 
23.75 ± 6.86 
81.36 ± 19.35 
<0.01 
3.17 ± 0.67 
2.42 ± 0.88 
76.62 ± 24.29 
< 0.01 
31.02 ± 6.38 
26.12 ± 7.49 
84.55 ± 18.16 
< 0.01 
4.00 ± 0.64 
2.95 ± 1.11 
73.53 ± 24.38 
< 0.0001 
0.51 ± 0.74 
*p < 0.05 is statistical significant. 
**Smaller positive values for this variable indicate greater improvement; the score is given 
only for assessment at the final visit. 
TABLE 7 : Adverse Events (No. and % of patients) [n=l5l] 
Adverse Events (AEs)  No. (%) of patients 
Somnolence 15 (9.9%) 
Dizziness 6 (4.0%) 
Tremor 5 (3.3%) 
Headache 4 (2.6%) 
Insomnia 4 (2.6%) 
Nausea 4 (2.6%) 
Anorexia 3 (2.0%) 
Akathisia 2 (1.3%) 
Sweating, diarrhoea, hypomania, extrapyramidal syndrome, 
urticaria, dry mouth, asthenia, chest pain, constipation, 
flatulence, retrosternal burning. 
Total AEs 
Total No. of patients with AEs 
1 (0.7%) each 
54 
31/151 (20.5%) 
(236) HAMDASetal 
TABLE 8 : Patients withdrawn from 
Patient Code Description of AEs 
02020 Hypomania 
Akathisia 
07015 Chest pain 
08001 Somnolence 
Constipation 
Anorexia 
Dizziness 
20 mg is shown in Table 4 and Fig. 1. 
Clinical response (>50% reduction over 
baseline in total HDRS score) was seen 
within 2 weeks in 36% of patients, within 
4 weeks in 83% patients and within 6 weeks 
in 93% of patients treated with FDC of 
olanzapine and fluoxetine (Fig. 2). 
One hundred and four patients (72%) in 
the per protocol population had HDRS total 
score of <7 after 6 weeks of treatment with 
FDC of olanzapine and fluoxetine and were 
considered as remitters (Table 5). 
Table 6 summarizes the results of analysis 
of the HDRS total score, HDRS Item No. 
1 (depressed mood) score, MADRS total 
score, CGI severity and improvement scores 
in the evaluable population. All the efficacy 
variables showed statistically significant 
decrease (p<0.01) at the end of treatment. 
Adverse Events 
One hundred and fifty one patients were 
safety evaluable. Adverse events were 
reported by 31 patients (20.5%) [Table 7]. 
Of these 31 patients, 18 were receiving 
treatment with one tablet of FDC of 
olanzapine 5 mg and fluoxetine 20 mg, 6 
with two tablets of olanzapine 5 mg/ 
fluoxetine 20 mg and 7 with three tablets 
of FDC of olanzapine 5 mg and fluoxetine 
20 mg. Somnolence was the most frequent 
adverse event reported by 15 patients (10%). 
Majority- of adverse events were mild in 
intensity-. Three patients were withdrawn 
because of adverse events (Table 8). All 
adverse events resolved satisfactorily. 
study due to Adverse Events 
Intensity Relation to treatment 
Mild 
Moderate 
Severe 
Moderate 
Mild 
Mild 
Mild 
Probable 
Probable 
Not related 
Possible 
Probable 
Possible 
Unrelated 
DISCUSSION 
Major depression is one of die most 
common mental illnesses. The high 
prevalence of depressive illness and its 
associated morbidity, mortality and economic 
consequences call for more effective and 
better tolerated treatments. Tricyclic agents 
(TCAs) have been the cornerstone of 
antidepressant therapy for many years but 
despite their undoubted efficacy, they have 
a non-selective mechanism of action. They 
affect reuptake of noradrenaline and 
serotonin, interact with several receptor 
subtypes (e.g., alpha adrenoreceptors, 
muscarinic and histamine H,-receptors) and 
are associated with unwanted anticholinergic, 
central nervous system and cardiovascular 
effects which limit their use particularly in 
elderly patients and in those with cardiac 
disease. Similarly, monoamine oxidase 
inhibitors (MAOIs) are effective in the 
treatment of depression but have a poor 
tolerability profile and the older agents (e.g., 
phenelizine, tranylcypromine) require dietary 
restriction to avoid hypertensive crisis. In 
the past decade, options for the treatment 
of depression were considerably increased 
with the introduction of selective serotonin 
reuptake inhibitor's (SSRls). The SSRls 
have comparable efficacy against depression 
but have an improved side effect profile. In 
clinical trials, compared with TCAs, SSRI 
have been associated with fewer adverse 
effects, particularly cardiovascular effects 
and a better safety- profile in overdose. 
However, approximately 30 to 40% of 
patients with depression fail to respond to 
(237) 
treatment with a single antidepressant agent. 
Subsequent medical therapy may include 
combinations of antidepressants or various 
augmentation strategies such as a combined 
antidepressant- antipsychotic approach. 
Atypical antipsychotic agents, such as 
olanzapine, cause fewer extrapyramidal 
adverse effects than conventional 
antipsychotics and has been shown to be 
an advantageous augmentation strategy for 
treatment-resistant depression. Olanzapine/ 
fluoxetine combination treatment has shown 
a significandy higher rate of response than 
monotherapy with olanzapine or fluoxetine 
(Shelton et al, 2001). In clinical studies 
(World Psychiatric Congress, 2000), 
olanzapine/fluoxetine combination patients 
showed numerically greater improvement on 
the Hamilton Depression Scale (HDRS) and 
statistically greater improvement in the 
Montgomery-Asberg Depression Rating 
Scale (MADRS) man either monotherapy. 
Additionally, olanzapine plus fluoxetine was 
associated with a statistically significant 
greater proportion of patients showing 
a >50% improvement on the MADRS. 
There were no significant differences between 
groups for extrapyramidal symptoms or 
significant adverse drug events. Further 
using MADRS for evaluation, meta-analysis 
of two double blind studies involving 797 
subjects diagnosed with non-psychotic, 
unipolar, treatment-resistant depression 
showed that olanzapine/ fluoxetine 
combination patients achieved significandy 
greater total score improvement (-7.31) at 
week 1 than olanzapine subjects (-5.18, 
p=0.013) or fluoxetine subjects (-5.26, 
p=0.004). This significant effect abided 
during eight weeks of treatment (endpoint: 
olanzapine/ fluoxetine combination -11.60, 
olanzapine -7.55, p<0.01; fluoxetine -8.73, 
p<0.01). 
The present study was conducted to test 
the efficacy of olanzapine and fluoxetine in 
treatment of Indian patients with severe or 
resistant depression. One hundred and 
eleven patients (77%) received treatment 
with one tablet of FDC of olanzapine 5 
mg and fluoxetine 20 mg once daily for 6 
weeks; in 20 patients (14%) the dose was 
stepped up to 2 tablets (i.e., olanzapine 10 
mg/ fluoxetine 40 mg) once a day and in 
13 patients (9%) the dose required further 
to be stepped up to 3 tablets (i.e., olanzapine OLANZAPINE AND FLUOXETINE COMBINATION IN DEPRESSION 
15 mg/ fluoxetine 60 mg) per day. A 
cumulative response rate of 89% (in the 
intent-to-treat population) was achieved at 
the end of 6 weeks of therapy. The drug 
was well tolerated; 2% of patients had to 
discontinue therapy with FDC of olanzapine 
and fluoxetine due to adverse events. 
It appears that combined administration 
of olanzapine and fluoxetine results in 
pharmacodynamic synergy and a 
neurochemical basis for the synergistic 
antidepressant effect has been suggested 
(Shelton et al, 2001). 
CONCLUSION 
FDC of olanzapine 5 mg and Fluoxetine 
20 mg once daily may be an effective and 
safe for the treatment of patients with 
severe or treatment resistant depression. 
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